Bilateral implant reconstruction does not affect the quality of postmastectomy radiation therapy
Creators
- 1. Department of Radiation Oncology, Memorial Sloan-Kettering Cancer Center, New York, NY (United States)
- 2. Drexel University College of Medicine, Philadelphia, PA (United States)
- 3. Department of Radiation Oncology, Mount Sinai School of Medicine, New York, NY (United States)
- 4. Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, New York (United States)
- 5. Department of Plastic Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY (United States)
- 6. Department of Biostatistics and Epidemiology, Memorial Sloan-Kettering Cancer Center, New York, NY (United States)
- 7. Department of Medical Physics, Memorial Sloan-Kettering Cancer Center, New York, NY (United States)
Description
To determine if the presence of bilateral implants, in addition to other anatomic and treatment-related variables, affects coverage of the target volume and dose to the heart and lung in patients receiving postmastectomy radiation therapy (PMRT). A total of 197 consecutive women with breast cancer underwent mastectomy and immediate tissue expander (TE) placement, with or without exchange for a permanent implant (PI) before radiation therapy at our center. PMRT was delivered with 2 tangential beams + supraclavicular lymph node field (50 Gy). Patients were grouped by implant number: 51% unilateral (100) and 49% bilateral (97). The planning target volume (PTV) (defined as implant + chest wall + nodes), heart, and ipsilateral lung were contoured and the following parameters were abstracted from dose-volume histogram (DVH) data: PTV D95% > 98%, Lung V20Gy > 30%, and Heart V25Gy > 5%. Univariate (UVA) and multivariate analyses (MVA) were performed to determine the association of variables with these parameters. The 2 groups were well balanced for implant type and volume, internal mammary node (IMN) treatment, and laterality. In the entire cohort, 90% had PTV D95% > 98%, indicating excellent coverage of the chest wall. Of the patients, 27% had high lung doses (V20Gy > 30%) and 16% had high heart doses (V25Gy > 5%). No significant factors were associated with suboptimal PTV coverage. On MVA, IMN treatment was found to be highly associated with high lung and heart doses (both p < 0.0001), but implant number was not (p = 0.54). In patients with bilateral implants, IMN treatment was the only predictor of dose to the contralateral implant (p = 0.001). In conclusion, bilateral implants do not compromise coverage of the target volume or increase lung and heart dose in patients receiving PMRT. The most important predictor of high lung and heart doses in patients with implant-based reconstruction, whether unilateral or bilateral, is treatment of the IMNs. Refinement of radiation techniques in reconstructed patients who require comprehensive nodal irradiation is warranted
Availability note (English)
Available from http://dx.doi.org/10.1016/j.meddos.2013.08.008Additional details
Identifiers
- DOI
- 10.1016/j.meddos.2013.08.008;
- PII
- S0958-3947(13)00097-6;
Publishing Information
- Journal Title
- Medical Dosimetry
- Journal Volume
- 39
- Journal Issue
- 1
- Journal Page Range
- p. 18-22
- ISSN
- 0958-3947
INIS
- Country of Publication
- United States
- Country of Input or Organization
- International Atomic Energy Agency (IAEA)
- INIS RN
- 45089193
- Subject category
- S62: RADIOLOGY AND NUCLEAR MEDICINE;
- Descriptors DEI
- ANIMAL TISSUES; CHEST; HEART; IRRADIATION; LUNGS; LYMPH NODES; MAMMARY GLANDS; MULTIVARIATE ANALYSIS; NEOPLASMS; PATIENTS; RADIATION DOSES; RADIATION SOURCE IMPLANTS; RADIOTHERAPY
- Descriptors DEC
- BODY; CARDIOVASCULAR SYSTEM; DISEASES; DOSES; GLANDS; IMPLANTS; LYMPHATIC SYSTEM; MATHEMATICS; MEDICINE; NUCLEAR MEDICINE; ORGANS; RADIATION SOURCES; RADIOLOGY; RESPIRATORY SYSTEM; STATISTICS; THERAPY
Optional Information
- Copyright
- Copyright (c) 2014 Elsevier Science B.V., Amsterdam, The Netherlands, All rights reserved.